Etakrinik asit etkileşimleri

Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol. (Amikasin etiketi, İlaç etkileşimleri)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because… (Etakrinik asit etiketi, Uyarılar)

In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (Dofetilid etiketi, İlaç etkileşimleri)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Gentamisin etiketi, Kutulu uyarı)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomisin etiketi, Kutulu uyarı)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (Tobramisin etiketi, İlaç etkileşimleri)

Like other diuretics it may precipitate hepatic coma and death. (Etakrinik asit etiketi, Uyarılar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

…Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (Adrenalin etiketi, İlaç etkileşimleri)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Aliskiren etiketi, Uyarılar ve önlemler)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Alogliptin ve metformin etiketi, İlaç etkileşimleri)

Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (Amiodaron etiketi, Uyarılar ve önlemler)

Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Amlodipin ve benazepril etiketi, Uyarılar ve önlemler)

In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (Amlodipin ve olmesartan etiketi, Uyarılar ve önlemler)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (Amlodipin ve valsartan etiketi, Uyarılar ve önlemler)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (Asebutolol etiketi, Uyarılar)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Atenolol etiketi, Uyarılar)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (Azilsartan etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Benazepril etiketi, Uyarılar ve önlemler)

Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Dapagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Dapagliflozin ve metformin etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

• Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

The concomitant administration of thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of PROGLYCEM. (Diazoksit etiketi, İlaç etkileşimleri)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (Diklorfenamid etiketi, İlaç etkileşimleri)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin etiketi, Uyarılar ve önlemler)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin ve metformin etiketi, Uyarılar ve önlemler)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalapril etiketi, Uyarılar ve önlemler)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Esmolol etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fentanil etiketi, Uyarılar ve önlemler)

In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (Fentermin ve topiramat etiketi, Uyarılar ve önlemler)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (Flukonazol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fluoksetin etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Diuretics: Use with caution. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fluvoksamin etiketi, Uyarılar ve önlemler)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

• Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Fosinopril etiketi, Uyarılar)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

…danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Glimepirid etiketi, İlaç etkileşimleri)

…may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (Glipizid etiketi, İlaç etkileşimleri)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidromorfon etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin aspart etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin degludek etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin detemir etiketi, İlaç etkileşimleri)

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (İnsülin glarjin etiketi, İlaç etkileşimleri)

Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin lispro etiketi, İlaç etkileşimleri)

Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (İrbesartan etiketi, Uyarılar ve önlemler)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Kanagliflozin etiketi, Uyarılar ve önlemler)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Kandesartan etiketi, Uyarılar ve önlemler)

Hypotension Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS : Drug Interactions ). (Kaptopril etiketi, Uyarılar)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Karbamazepin etiketi, Uyarılar ve önlemler)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (Ketokonazol etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (Kinidin etiketi, İlaç etkileşimleri)

Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Kodein etiketi, İlaç etkileşimleri)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Kolestiramin etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Levorfanol etiketi, İlaç etkileşimleri)

Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Levosalbutamol etiketi, İlaç etkileşimleri)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Linezolid etiketi, Uyarılar ve önlemler)

Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. (Lisinopril etiketi, Uyarılar ve önlemler)

Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions ). (Etakrinik asit etiketi, Uyarılar)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (Losartan etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (Mekamilamin etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Metadon etiketi, Uyarılar ve önlemler)

Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (Metoprolol etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

Symptomatic hypotension is most likely to occur in patients who have been salt- and volume- depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (Moeksipril etiketi, Uyarılar)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Morfin etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Nadolol etiketi, Uyarılar)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Nalbufin etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (Nifedipin etiketi, İlaç etkileşimleri)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksimorfon etiketi, İlaç etkileşimleri)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oliseridin etiketi, İlaç etkileşimleri)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (Olmesartan etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol ve sodyum bikarbonat etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Parasetamol ve kodein etiketi, İlaç etkileşimleri)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Paroksetin etiketi, Uyarılar ve önlemler)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Pentazosin ve nalokson etiketi, İlaç etkileşimleri)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been volume or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting [see Dosage and Administration (2.1) ] . (Perindopril etiketi, Uyarılar ve önlemler)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Petidin etiketi, İlaç etkileşimleri)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Pindolol etiketi, Uyarılar)

…danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (Prazosin etiketi, Uyarılar)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

Diuretics : Codeine may reduce the efficacy of diuretics. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (Ramipril etiketi, Uyarılar ve önlemler)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (Sakubitril ve valsartan etiketi, Uyarılar ve önlemler)

Diuretics: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

• Diuretics: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

…inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone… (Siklofosfamid etiketi, İlaç etkileşimleri)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Sotalol etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

Drug Interactions In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. (Sülfametoksazol ve trimetoprim etiketi, İlaç etkileşimleri)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tapentadol etiketi, İlaç etkileşimleri)

Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (Telmisartan etiketi, Uyarılar ve önlemler)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (Telmisartan ve amlodipin etiketi, Uyarılar ve önlemler)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (Terazosin etiketi, Uyarılar ve önlemler)

Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol etiketi, İlaç etkileşimleri)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol ve parasetamol etiketi, İlaç etkileşimleri)

Symptomatic hypotension is most likely to occur in patients who have been salt- or volume-depleted as a result of prolonged treatment with diuretics, dietary salt restriction, dialysis, diarrhea, or vomiting. (Trandolapril etiketi, Uyarılar)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

• Diuretics: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (Valsartan etiketi, Uyarılar ve önlemler)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Etakrinik asit etiketi, İlaç etkileşimleri)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Venlafaksin etiketi, Uyarılar ve önlemler)

Control patients with milder ventricular dysfunction, if possible, with optimum doses of digitalis and/or diuretics before verapamil treatment is started [see Drug Interactions ( 7.5 )] . (Verapamil etiketi, Uyarılar ve önlemler)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Akarboz etiketi, İlaç etkileşimleri)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, beta-blockers should be administered cautiously. (Betaksolol etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (Dronedaron etiketi, Uyarılar ve önlemler)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

…clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (Finasterid etiketi, İlaç etkileşimleri)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (Flekainid etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glibenklamid etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glipizid ve metformin etiketi, Önlemler)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (Hidralazin etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (İmatinib etiketi, Uyarılar ve önlemler)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (İsradipin etiketi, İlaç etkileşimleri)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Linagliptin ve metformin etiketi, İlaç etkileşimleri)

Kıvrım (loop) diüretiklerinin ve tiyazid diüretiklerin uzun süreli kullanımı idrarla magnezyum kaybını artırır. (NIH Office of Dietary Supplements, Magnesium)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (Nisoldipin etiketi, İlaç etkileşimleri)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (Nitroprussid etiketi, Uyarılar)

The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (Penisilin G etiketi, İlaç etkileşimleri)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (Piperasilin ve tazobaktam etiketi, Uyarılar ve önlemler)

Kıvrım (loop) diüretikleri ve tiyazid diüretikler potasyum kaybını artırır; bazen bunlarla birlikte takviye reçete edilir. (NIH Office of Dietary Supplements, Potassium)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinid etiketi, İlaç etkileşimleri)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Sülfadiazin etiketi, İlaç etkileşimleri)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Terbinafin etiketi, İlaç etkileşimleri)

Care should also be exercised in patients receiving potassium-depleting steroids. (Etakrinik asit etiketi, Uyarılar)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)